arrow

From NeuroLex

Revision as of 11:25, 16 March 2010 by Bandrow (Talk | contribs)
Jump to: navigation, search



Deferasirox

Name: Deferasirox
Description: Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved in the USA for this purpose. Pharmacology: Deferasirox is an orally active chelator that is selective for iron (as Fe3+). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper there are variable decreases in the serum concentration of these trace metals after the administration of deferasirox. The clinical significance of these decreases is uncertain. Mechanism of action: Deferasirox works in treating iron toxicity by binding trivalent (ferric) iron (for which it has a strong affinity), forming a stable complex which is eliminated via the kidneys. Drug type: Approved. Investigational. Small Molecule. Drug category: Iron Chelating Agents
Synonym(s): Deferasiroxum (inn-latin), ICL 670, deferasirox, Exjade
Has role: Drug
Super-category: Molecule
URL: http://www.drugbank.ca/drugs/DB01609
Id: CHEBI: 49005
Link to OWL / RDF: Download this content as OWL/RDF


Contributors

Bandrow, Ccdbuser, Nifbot2



bookmark
Facts about DeferasiroxRDF feed
Commenttaken from DrugBank
CurationStatusuncurated  +
CuratorAb  +
DefiningCitationhttp://www.drugbank.ca/drugs/DB01609  +
DefinitionDeferasirox is an oral iron chelator. Its Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved in the USA for this purpose. Pharmacology: Deferasirox is an orally active chelator that is selective for iron (as Fe3+). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper there are variable decreases in the serum concentration of these trace metals after the administration of deferasirox. The clinical significance of these decreases is uncertain. Mechanism of action: Deferasirox works in treating iron toxicity by binding trivalent (ferric) iron (for which it has a strong affinity), forming a stable complex which is eliminated via the kidneys. Drug type: Approved. Investigational. Small Molecule. Drug category: Iron Chelating Agents cule. Drug category: Iron Chelating Agents
Has roleDrug  +
IdCHEBI: 49005  +
LabelDeferasirox  +
ModifiedDate17 March 2010  +
SuperCategoryMolecule  +
SynonymDeferasiroxum (inn-latin)  +, ICL 670  +, deferasirox  +, and Exjade  +